Shangjian Bio-CD38/CD47 double antibody was approved for clinical use in the U.S.

ArticleMedicine Guanlan

On November 22, Suntech announced that its self-developed world's first targeting CD38/CD47 double antibody SG2501 has been approved by the US FDA for clinical research

CD38 molecule is a single-chain type II transmembrane glycoprotein, which is widely expressed in hematopoietic cells and non-hematopoietic cell lines, and has many complex and unique biological characteristics and functions

CD47 is a glycoprotein widely expressed on the surface of a variety of cancer cells.

According to the press release, SG2501 is an anti-CD38/CD47 double antibody developed based on the BIMA double antibody platform of Suntech.

It is worth mentioning that, based on the BIMA double antibody platform, Sunkin Bio has also developed a number of "1+1>2" double antibody projects, two of which have been approved for clinical use

Reference

[1] Shangjian Biological announced that the world’s first bi-antibody of its kind, SG2501, was approved by the FDA for clinical use.

[2]Sumgen Bio Official Website.